natgillin/translations-raw huggingface dataset:
This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. 
To je bilo dokazano s klinično pomembnim in statistično značilnim zmanjšanjem vrednosti glikoziliranega hemoglobina (HbA1c) in vrednosti glukoze v plazmi na tešče v primerjavi s kontrolo od izhodišča do končne opazovane vrednosti v študiji.
In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing anti-diabetic and cardiovascular therapy, for up to 3.5 years. 
V študiji kardiovaskularnih izidov PROactive je bilo 5.238 bolnikov s sladkorno boleznijo tipa 2 in predhodno obstoječo hudo makrovaskularno boleznijo randomiziranih na pioglitazon ali placebo, oboje kot dodatek k dotedanjemu antidiabetičnemu in kardiovaskularnemu zdravljenju, in sicer za obdobje do 3,5 let.
Risk related to pioglitazone 
Tveganja, povezana s pioglitazonom
• as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance. 
• kot dodatek k dieti in telesni vadbi za izboljšanje urejenosti glikemije pri odraslih bolnikih (še posebej bolnikih s prekomerno telesno maso) z neustrezno urejeno sladkorno boleznijo pri zdravljenju samo s pioglitazonom in pri katerih uporaba metformina zaradi kontraindikacij ali intolerance ni primerna.
DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP (glucosedependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. 
DPP-4 je glavni encim, ki sodeluje pri hitri razgradnji inkretinov, glukagonu podobnega peptida-1 (GLP-1; “glucagon-like peptide-1”) in od glukoze odvisnega insulinotropnega polipeptida (GIP; “glucose-dependent insulinotropic polypeptide”), ki se izločata iz črevesa, njuna koncentracija pa se po obroku zviša.
Any macroscopic haematuria should be investigated before starting therapy. 
Pred uvedbo zdravljenja je treba raziskati vsako makroskopsko hematurijo.
The incidence of hypoglycaemia was greater when alogliptin was used as triple therapy with pioglitazone and metformin (compared to active-control). 
Pojavnost hipoglikemije je bila večja, če je bil alogliptin uporabljen v okviru trotirnega zdravljenja s pioglitazonom in z metforminom (v primerjavi s kontrolnim zdravilom).
Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see above and section 4.2). 
Zaradi ohranjanja sistemskih izpostavljenosti alogliptinu, podobnih tistim, ki so bile opažene pri bolnikih z normalnim delovanjem ledvic, je pri bolnikih z zmerno ali s hudo okvaro ledvic ali bolnikih s končno ledvično odpovedjo, ki se zdravijo z dializo, treba uporabljati manjše odmerke alogliptina (glejte zgoraj in poglavje 4.2).
- if you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, glibenclamide) or insulin. 
• če jemljete zdravilo za zdravljenje sladkorne bolezni, znano kot sulfonilsečnina (npr. glipizid, tolbutamid, glibenklamid), ali uporabljate insulin.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance. 
Dokazano je bilo, da zdravljenje s pioglitazonom zmanjša sproščanje glukoze iz jeter in poveča periferno porabo glukoze v primeru odpornosti proti insulinu.
There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9 and 3A4 in man. 
Pri človeku ni indukcije glavnih inducibilnih izoencimov P450 1A, 2C8/9 in 3A4.
Studies in animals with alogliptin plus pioglitazone as combination treatment have shown reproductive toxicity (slight augmentation of pioglitazone-related foetal growth retardation and foetal visceral variations, see section 5.3). 
Študije kombiniranega zdravljenja z alogliptinom in pioglitazonom na živalih so pokazale vpliv na sposobnost razmnoževanja (rahlo povečanje zaostanka rasti plodov in visceralne variacije pri plodovih, povezanih z uporabo pioglitazona, glejte poglavje 5.3).
For patients intolerant to metformin or for whom metformin is contraindicated, inadequately controlled on pioglitazone alone, the recommended dose of Incresync is one tablet of 25 mg/30 mg or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken. 
Pri bolnikih, ki metformina ne prenašajo ali pa je njegova uporaba kontraindicirana, pri zdravljenju samo s pioglitazonom pa urejenost sladkorne bolezni ni zadostna, je priporočeni odmerek zdravila Incresync ena tableta 25 mg/30 mg ali 25 mg/45 mg enkrat na dan, odvisno od odmerka pioglitazona, ki ga bolnik že jemlje.
Since there is a potential for an increase in dose-related adverse reactions, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih učinkov, bo pri sočasni uporabi gemfibrozila odmerek pioglitazona morda treba zmanjšati.
Minimal to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect level). 
Pri samcih podgan so pri najnižjih uporabljenih odmerkih (27-kratna izpostavljenost človeka) poročali o minimalni do blagi enostavni hiperplaziji prehodnih celic sečnega mehurja, vendar pa jasna mejna vrednost brez opaženega učinka (NOEL; “no observed effect level”) ni bila ugotovljena.
In combination studies, pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. 
V študijah kombiniranega zdravljenja je pioglitazon, dodan k metforminu, povzročil povprečno povečanje telesne mase v enem letu za 1,5 kg, pioglitazon, dodan k sulfonilsečnini, pa za 2,8 kg.
In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg. 
V primerjalnih skupinah je dodatek sulfonilsečnine k metforminu povzročil povprečno povečanje telesne mase za 1,3 kg, dodatek metformina k sulfonilsečnini pa povprečno zmanjšanje telesne mase za 1,0 kg.
The recommended dose is one tablet of 25 mg/30 mg or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken. 
Priporočeni odmerek je ena tableta 25 mg/30 mg ali 25 mg/45 mg enkrat na dan, odvisno od odmerka pioglitazona, ki ga bolnik že jemlje.
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. 
Pri bolnikih z zmerno ali s hudo okvaro ledvic ali s končno ledvično odpovedjo na hemodializi so opazili približno 2-kratno oziroma 4-kratno povečanje sistemske izpostavljenosti alogliptinu.
In clinical studies with pioglitazone, there was evidence of dose-related weight gain, which may be due to fat accumulation and, in some cases, associated with fluid retention. 
V kliničnih študijah pioglitazona so opazili od odmerka odvisno povečanje telesne mase, ki je lahko posledica kopičenja maščobe, v nekaterih primerih pa je lahko povezano z zastajanjem tekočine.
In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin. 
Pri zdravih osebah alogliptin pri sočasni uporabi z varfarinom ni vplival na protrombinski čas ali internacionalno normalizirano razmerje (INR).
Microcrystalline cellulose Hydroxypropylcellulose Croscarmellose sodium Magnesium stearate Lactose monohydrate 
Jedro tablete manitol mikrokristalna celuloza hidroksipropilceluloza premreženi natrijev karmelozat magnezijev stearat laktoza monohidrat
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
V 3,5 let trajajoči študiji PROactive so o zlomih poročali pri 44/870 žensk (5,1 %), ki so se zdravile s pioglitazonom, v primerjavi s 23/905 žensk (2,5 %), ki so se zdravile s primerjalnim zdravilom.
Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). 
Pri hemodializi se odstranijo le majhne količine alogliptina (med 3-urno hemodializo se ga je odstranilo le približno 7 %).
Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (< 1% of the parent compound), and N-acetylated alogliptin, M-II (< 6% of the parent compound). 
Po uporabi peroralnega odmerka z radioaktivnim izotopom označenega [14C] alogliptina sta bila zaznana dva manj pomembna presnovka, in sicer N-demetiliran alogliptin, M-I (< 1 % izvorne spojine), in N-acetiliran alogliptin, M-II (< 6 % izvorne spojine).
Table 1: Adverse reactions System organ class Adverse reaction 
Preglednica 1: Neželeni učinki Organski sistem Neželeni učinek
Thus, free (unbound) pioglitazone concentration is unchanged (see section 4.2). 
Zato je koncentracija prostega (nevezanega) pioglitazona nespremenjena (glejte poglavje 4.2).
Visceral fat was significantly decreased while there was an increase in extra-abdominal fat mass. 
Visceralno maščevje se je značilno zmanjšalo, masa zunajtrebušnega maščevja pa se je povečala.
Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to control subjects. 
Pri bolnikih z zmerno okvaro jeter je bila skupna izpostavljenost alogliptinu približno za 10 % manjša, največja izpostavljenost pa približno za 8 % manjša v primerjavi s kontrolnimi osebami.
A total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of co-administered alogliptin and pioglitazone on glycaemic control and their safety. 
Skupno 3.504 bolniki s sladkorno boleznijo tipa 2, vključno s 1.908 bolniki, zdravljenimi z alogliptinom in s pioglitazonom, so bili vključeni v 4 dvojno slepe, s placebom ali z zdravilno učinkovino nadzorovane klinične študije 3. faze, z namenom ovrednotenja učinkov sočasne uporabe alogliptina in pioglitazona na urejenost glikemije in njuno varnost.
Frequency of adverse reactions Alogliptin Pioglitazone Incresync 
Pogostnost neželenih učinkov Alogliptin Pioglitazone
Symptoms of a serious allergic reaction may include; rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. 
Simptomi hude alergijske reakcije lahko vključujejo izpuščaj, izbokle rdeče izpuščaje na koži (koprivnica), otekanje obraza, ustnic, jezika in žrela, kar lahko povzroči težave pri dihanju ali požiranju.
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2. 
V kliničnih študijah alogliptin ni imel klinično pomembnega vpliva na farmakokinetiko kofeina, (R)-varfarina, pioglitazona, gliburida, tolbutamida, (S)-varfarina, dekstrometorfana, atorvastatina, midazolama, peroralnega kontraceptiva (noretindron in etinilestradiol), digoksina, feksofenadina, metformina ali cimetidina, s čimer je bila in vivo dokazana majhna nagnjenost k medsebojnemu delovanju s substrati za CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glikoprotein in OCT2.
Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria. 
Spontana poročila o preobčutljivostnih reakcijah med spremljanjem zdravila v obdobju trženja pri bolnikih, zdravljenih s pioglitazonom, vključujejo anafilaksijo, angioedem in urtikarijo.
Due to the increased risk of hypoglycaemia in combination with metformin, a lower dose of metformin or the pioglitazone component may be considered to reduce the risk of hypoglycaemia when this combination is used (see section 4.2). 
Zaradi večjega tveganja za hipoglikemijo pri kombiniranem zdravljenju z metforminom, je v primeru zdravljenja s takšno kombinacijo treba razmisliti o zmanjšanju odmerka metformina ali manjšem odmerku pioglitazona, da se zmanjša tveganje za pojav hipoglikemije (glejte poglavje 4.2).
In patients with renal impairment, serum concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. 
Pri bolnikih z okvaro ledvic so koncentracije pioglitazona in njegovih presnovkov v serumu manjše kot pri osebah z normalnim delovanjem ledvic, peroralni očistek izvorne učinkovine pa je pri obojih podoben.
In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence. 
V kliničnih študijah z alogliptinom je bila pojavnost anafilaktičnih reakcij majhna.
Overall, treatment with the recommended daily dose of 25 mg alogliptin in combination with pioglitazone improved glycaemic control. 
Zdravljenje z alogliptinom v priporočenem dnevnem odmerku 25 mg v kombinaciji s pioglitazonom je na splošno izboljšalo urejenost glikemije.
Co-administration of 25 mg alogliptin once daily and 45 mg pioglitazone once daily for 12 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin, pioglitazone or their active metabolites. 
Pri sočasni 12-dnevni uporabi alogliptina v odmerku 25 mg enkrat na dan in pioglitazona v odmerku 45 mg enkrat na dan pri zdravih osebah niso opazili klinično pomembnih učinkov na farmakokinetiko alogliptina, pioglitazona ali njunih aktivnih presnovkov.
Elimination Alogliptin was eliminated with a mean terminal half-life (T1/2) of approximately 21 hours. 
Izločanje Povprečni končni razpolovni čas (T1/2) izločanja alogliptina znaša približno 21 ur.
It is unknown whether alogliptin and pioglitazone are excreted in human milk. 
Ni znano, ali se alogliptin in pioglitazon izločata v materino mleko.
Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high. 
Alogliptin tako izboljša urejenost glikemije preko od glukoze odvisnega mehanizma, pri čemer se pri visokih vrednostih glukoze okrepi izločanje insulina in zmanjša količina glukagona.
There are no data from the use of Incresync in pregnant women. 
Podatkov o uporabi zdravila Incresync pri nosečnicah ni.
No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus. 
Pri ponavljajočem se odmerjanju niso opazili klinično pomembnega kopičenja niti pri zdravih osebah niti pri bolnikih s sladkorno boleznijo tipa 2.
These studies evaluated the effects of co-administered alogliptin and pioglitazone on glycaemic control and their safety as initial combination therapy, as dual therapy in patients initially treated with pioglitazone alone (with or without metformin or a sulphonylurea), and as add-on therapy to metformin. 
Te študije so vrednotile učinke sočasne uporabe alogliptina in pioglitazona na urejenost glikemije in njuno varnost v okviru začetnega kombiniranega zdravljenja, kombiniranega zdravljenja pri bolnikih, ki so se najprej zdravili samo s pioglitazonom (z metforminom ali s sulfonilsečnino ali brez), in dodatka k zdravljenju z metforminom.
In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). 
Študije in vitro kažejo, da alogliptin v koncentracijah, doseženih s priporočenim odmerkom 25 mg alogliptina, ne zavira in ne inducira izooblik CYP 450 (glejte poglavje 5.2).
Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke] 
Primarni sestavljeni opazovani dogodek [prvi dogodek kardiovaskularne smrti, neusodnega miokardnega infarkta in neusodne možganske kapi]
In active comparator-controlled studies, mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
V s primerjalnim zdravilom nadziranih študij je povprečno povečanje telesne mase pri samostojnem zdravljenju s pioglitazonom znašalo 2-3 kg v obdobju enega leta.
No data are available with regard to overdose of Incresync. 
Podatki o prevelikem odmerjanju zdravila Incresync niso na voljo.
Add-on combination therapy placebo-controlled studies Alogliptin 25 mg once daily with pioglitazone ± metformin or a sulphonylurea (n=195) FAS = full analysis set LOCF = last observation carried forward † Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values * p<0.001 compared to placebo or placebo+combination treatment 
S placebom nadzorovane študije dodatnega kombiniranega zdravljenja Alogliptin 25 mg enkrat na dan s pioglitazonom ± metformin ali sulfonilsečnina (n=195) FAS = vsi vključeni bolniki (“full analysis set”) LOCF = prenos zadnjih opaženih vrednosti naprej (“last observation carried forward”) † Srednja vrednost najmanjših kvadratov, prilagojena gleda na predhodno antihiperglikemično zdravljenje in vrednosti v izhodišču * p<0,001 v primerjavi s placebom ali placebom + kombiniranim zdravljenjem
For patients with moderate renal impairment (CrCl ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered. 
Pri bolnikih z zmerno okvaro ledvic (CrCl ≥ 30 do ≤ 50 ml/min) je treba uporabiti polovico priporočenega odmerka alogliptina.
There have been rare reports of hepatocellular dysfunction during post-marketing experience with pioglitazone (see section 4.8). 
Med spremljanjem pioglitazona v obdobju trženja so poročali o redkih primerih hepatocelularne disfunkcije (glejte poglavje 4.8).
In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per 1,000 patient years, respectively. 
V združeni analizi podatkov iz 13 študij je celotni delež poročil o vnetju trebušne slinavke pri bolnikih, ki so prejemali 25 mg alogliptina, 12,5 mg alogliptina, aktivno kontrolo ali placebo znašal 2, 1, 1 oziroma 0 dogodkov na 1.000 bolnikov-let (“patient years”).
For patients with moderate renal impairment, Incresync 12.5 mg/30 mg or 12.5 mg/45 mg should be administered once daily. 
Pri bolnikih z zmerno okvaro ledvic je treba zdravilo Incresync 12,5 mg/30 mg ali 12,5 mg/45 mg uporabljati enkrat na dan.
How to take Incresync 
Kako jemati zdravilo Incresync
No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. 
Neželenih učinkov alogliptina na plodnost, sposobnost za razmnoževanje ali zgodnji razvoj zarodkov pri podganah do sistemske izpostavljenosti, ki je bila veliko večja od izpostavljenosti človeka pri priporočenem odmerku, niso opazili.
In light of age-related risks (especially bladder cancer, fractures and heart failure associated with the pioglitazone component), the balance of benefits and risks should be considered carefully both before and during Incresync treatment in the elderly. 
Zaradi tveganj, povezanih s starostjo (še posebej rak mehurja, zlomi in srčno popuščanje, povezani s pioglitazonom), je pri starostnikih pred uvedbo zdravljenja z zdravilom Incresync in med njim treba skrbno pretehtati razmerje med koristmi in tveganji.
The (S)-enantiomer is not detectable at therapeutic doses. 
(S)-enantiomer pri terapevtskih odmerkih ni zaznaven.
In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14]. 
V skupini, ki je prejemala alogliptin, so o dogodku iz sklopa sekundarnega sestavljenega opazovanega dogodka MACE poročali pri 12,7 % oseb (344), v skupini, ki je prejemala placebo, pa pri 13,4 % oseb (359) [razmerje ogroženosti = 0,95; 1-stranski 99 % interval zaupanja: 0-1,14].
Eye disorders visual disturbance common macular oedema not known 
Očesne bolezni motnje vida pogosti makularni edem neznana
In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4). 
Zaradi tveganj, ki so povezana z dolgotrajnim zdravljenjem s pioglitazonom, morajo zdravniki pri nadaljnjih obiskih rutinsko preverjati, če je korist zdravila Incresync še prisotna (glejte poglavje 4.4).
When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL. 
Srednje s placebom korigirano zmanjšanje povprečnih postprandialnih koncentracij glukoze 4 ure po zajtrku, kosilu in večerji je pri 14-dnevnem zdravljenju z alogliptinom v odmerku 25 mg v primerjavi z izhodiščem znašalo -35,2 mg/dl.
Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, 
Simptomi lahko vključujejo: tresenje, znojenje, tesnobo, zamegljen vid,
• in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. 
• v kombinaciji z metforminom (tj. trotirno kombinirano zdravljenje) kot dodatek k dieti in telesni vadbi za izboljšanje urejenosti glikemije pri odraslih bolnikih (še posebej bolnikih s prekomerno telesno maso) z neustrezno urejeno sladkorno boleznijo pri zdravljenju z metforminom v največjem odmerku, ki ga prenašajo, in s pioglitazonom.
Acute pancreatitis is a serious adverse reaction and is attributed to the alogliptin component of Incresync (see section 4.4). 
Akutni pankreatitis je resen neželeni učinek, ki ga je mogoče pripisati vsebnosti alogliptina v zdravilu Incresync (glejte poglavje 4.4).
Pioglitazone did not cause statistically significant increases in LDL-cholesterol levels compared to placebo whilst reductions were observed with metformin and gliclazide. 
Pioglitazon v primerjavi s placebom ni statistično pomembno zvišal koncentracije holesterola LDL, pri metforminu in gliklazidu pa so zabeležili njeno znižanje.
Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF) 
Preglednica 3: Sprememba vrednosti HbA1c (%) od izhodišča pri uporabi alogliptina v odmerku 25 mg v z učinkovino nadzorovani študiji (PPS, LOCF) Študija
No dose adjustment is necessary (see section 4.2). 
Odmerka ni treba prilagajati (glejte poglavje 4.2).
It is recommended, therefore, that patients treated with Incresync undergo periodic monitoring of liver enzymes. 
Pri bolnikih, ki se zdravijo z zdravilom Incresync, je priporočljivo redno spremljanje vrednosti jetrnih encimov.
Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged active substance in the urine. 
60-70 % odmerka učinkovine se izloči z urinom v nespremenjeni obliki.